Join Dr Fred Beasley to learn more about the key factors to consider when choosing the right rodent model for preclinical obesity studies. Explore how to establish study aims for obesity research, the conventional and next generation obesity models available, and best practice in study design.

Learn how a barcode deep NGS-based method enables highly sensitive characterization of cell lines, xenografts, organoids, and patient samples. Discover how this novel and robust method is used to determine identity, detect contamination, and annotate mouse and human samples.

Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.

Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.

Join Dr Sheng Guo to learn how to maximize your oncology in vitro datasets using in silico modeling. Find out how advanced data analysis is used to interrogate cell line and organoid genomics, novel combination regimens, and predictive biomarkers.

Explore three strategies for biomarker discovery and validation early in oncology drug development. Learn how translational preclinical models are used to identify and implement biomarkers across a range of studies, and how to transfer preclinical biomarkers to the clinic for improved accuracy and success rates.

Join Dr Henry Li, CrownBio CSO and Dr Sylvia Boj, HUB Scientific Director to learn more about HUB tumor organoids and their applications in oncology drug discovery. Find out why organoids better predict patient response, and how they are used to improve cancer drug candidates entering the clinic.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

Join Dr Thomas Scullion to learn how to leverage NHP exploratory toxicology studies to guide and answer multiple immunotherapy developmental questions including lead optimization, dosing paradigms, and immunogenicity endpoints. Discover how NHPs provide a more translational preclinical model for elucidating immune-related toxicity.